Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 37.45%-462.88K | 22.23%-245.37K | -89.86%-707.95K | 27.62%-1.71M | -103.05%-278.71K | -7.02%-739.96K | 68.42%-315.5K | 29.75%-372.88K | 13.27%-2.36M | -137.26K |
| Net income from continuing operations | 23.78%-504.05K | 62.02%-408.33K | -18.20%-602.73K | 15.78%-2.52M | 76.81%-275.25K | -30.68%-661.34K | -100.85%-1.08M | 33.40%-509.92K | 34.64%-2.99M | ---1.19M |
| Operating gains losses | 1,138.98%141.65K | -45.62%40.06K | -106.75%-5.41K | -184.09%-29.05K | -710.31%-194.3K | 147.85%11.43K | 175.24%73.65K | 51,163.69%80.17K | 148.65%34.55K | --31.84K |
| Depreciation and amortization | 124.53%3.2K | 1,798.48%22.52K | 1,202.42%15.04K | 8.91%4.94K | -3.15%1.17K | -28.00%1.43K | 439.09%1.19K | 2.76%1.16K | 39.82%4.53K | --1.21K |
| Asset impairment expenditure | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Unrealized gains and losses of investment securities | 46,047.63%14.68M | -6,473.33%-14.72M | 182.66%177K | 148.42%50.53K | -95.43%1.87K | 11.28%31.81K | 231.25%230.97K | -10,384.34%-214.12K | -108.46%-104.35K | --40.96K |
| Remuneration paid in stock | -80.54%13.36K | -73.71%18.05K | -66.75%22.83K | -37.51%163.23K | ---42.7K | --68.65K | --68.65K | --68.65K | --261.23K | ---- |
| Other non cashItems | -5,442.55%-315.26K | -2,053,980.00%-205.39K | -270.86%-105.01K | 25.63%72.71K | -90.77%5.34K | --5.9K | --10 | 6,146,000.00%61.46K | --57.88K | --57.88K |
| Change In working capital | -7,218.97%-14.48M | 3,795.17%15.01M | -250.05%-209.67K | 44.62%552.38K | -65.71%225.17K | -3.03%-197.84K | 222.48%385.31K | -39.73%139.73K | -52.57%381.95K | --656.72K |
| -Change in receivables | -66.99%-95.32K | -112.11%-3.51K | 464.93%34.51K | -125.97%-4.51K | -89.97%33.03K | 55.43%-57.08K | 118.76%29K | 67.88%-9.46K | 47.58%17.35K | --329.47K |
| -Change in prepaid assets | 181.43%46.17K | -35.47%45.12K | -34.94%51.71K | 391.11%33.98K | -122.11%-58.74K | 80.18%-56.69K | 396.36%69.92K | 1,550.02%79.49K | -32.10%-11.67K | --265.74K |
| -Change in payables and accrued expense | -17,066.71%-14.43M | 5,126.10%14.97M | -524.53%-295.89K | 38.97%522.91K | 307.87%250.89K | -137.85%-84.06K | 264.51%286.38K | -73.87%69.7K | -53.10%376.27K | --61.51K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 37.45%-462.88K | 22.22%-245.37K | -89.86%-707.95K | 27.62%-1.71M | -103.04%-278.71K | -7.02%-739.97K | 68.42%-315.49K | 29.75%-372.88K | 13.27%-2.36M | ---137.26K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26.82%-164.8K | -3.08K |
| Net PPE purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | --0 |
| Net intangibles purchas and sale | ---- | ---- | ---- | ---- | ---- | --0 | --0 | --0 | --0 | ---3.08K |
| Net investment purchase and sale | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | -28.81%-164.8K | --0 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | 26.82%-164.8K | ---3.08K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -38.58%473.13K | -44.13%164.38K | 101.60%778.37K | -31.64%1.7M | 73.84%252.56K | -9.35%770.35K | -69.37%294.21K | -28.00%386.09K | -16.34%2.49M | 145.28K |
| Net issuance payments of debt | 231.61%316.73K | -20.39%130.22K | 617.47%685.76K | -146.02%-863.24K | -201.63%-881.73K | -153.39%-240.66K | 34.99%163.57K | -78.09%95.58K | 87.22%1.88M | --867.61K |
| Net common stock issuance | --0 | --0 | --0 | 260.88%1.91M | 310.41%1.91M | --0 | --0 | --0 | -87.69%530.16K | ---909.27K |
| Net other financing activities | -84.53%156.39K | -73.85%34.17K | -68.12%92.61K | 661.47%653.23K | -516.66%-778.93K | 322.13%1.01M | -48.56%130.64K | 190.44%290.51K | 103.68%85.79K | --186.95K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -38.58%473.13K | -44.13%164.38K | 101.60%778.37K | -31.64%1.7M | 73.84%252.56K | -9.35%770.35K | -69.37%294.21K | -28.00%386.09K | -16.34%2.49M | --145.28K |
| Net cash flow | ||||||||||
| Beginning cash position | -86.08%1.02K | 186.47%82.02K | -24.79%11.59K | -67.17%15.42K | 260.06%37.74K | -60.01%7.36K | -44.58%28.63K | -67.17%15.42K | 258.81%46.95K | --10.48K |
| Current changes in cash | -66.27%10.25K | -280.74%-80.99K | 432.90%70.42K | 87.88%-3.82K | -630.06%-26.15K | 483.67%30.38K | 36.04%-21.27K | 180.34%13.22K | -193.12%-31.53K | --4.93K |
| End cash Position | -70.14%11.27K | -86.08%1.02K | 186.47%82.02K | -24.79%11.59K | -24.79%11.59K | 260.06%37.74K | -60.01%7.36K | -44.58%28.63K | -67.17%15.42K | --15.42K |
| Free cash from | 37.45%-462.88K | 22.22%-245.37K | -89.86%-707.95K | 27.62%-1.71M | -103.04%-278.71K | -7.02%-739.97K | 68.40%-315.49K | 29.84%-372.88K | 16.27%-2.36M | ---137.26K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.